Cas 1604810-83-4 CDK Inhibitors THZ1 Cdk7 Inhibitor Breast Cancer
Cas 1604810-83-4 CDK Inhibitors THZ1 Cdk7 Inhibitor Breast Cancer
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:THZ1 |
Purity:98% min |
|
CAS NO:1604810-83-4 |
Solubility:DMSO27 mg/mL (47.70 mM) |
|
Molecular Formula:C31H28ClN7O2 |
Package:Package according to customer requirements |
|
Molecular Weight:566.053 |
Storage:Store at -20℃ |
Quality control
Remarks
THZ1 is a selective CDK7 inhibitor that preferentially diminishes transcription in cancer cells. THZ1 has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. Cancer cell-line profiling indicates that a subset of cancer cell lines, including human T-cell acute lymphoblastic leukaemia (T-ALL), have exceptional sensitivity to THZ1. Cyclin-dependent kinases (CDKs) are involved in temporal control of the cell cycle and transcription and play central roles in cancer development and metastasis.
Related Products
Flavopiridol HCL; Flavopiridol; BMS-863233 HCl; Dinaciclib; AZD5438; Seliciclib; PalbociclibIsethionate; PHA-793887; RO-3306; Abemaciclib mesylate; Abemaciclib; JNJ-7706621
References
[1].Kwiatkowski N, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014 Jul 31;511(7511):616-20.
[2].Jiang YY, et al. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut. 2016 May 10. pii: gutjnl-2016-311818.
[3].Christensen CL, et al. Targeting transcriptional addictions in small cell lung cancer wi
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.